Mauro giacca, director general of the United Nations International Center for genetic engineering and biotechnology, visited Xinda: Xinda will become the best biopharmaceutical company in China

Source: Xinda biology 2017-2-20 peace and health is the common hope of all mankind With the continuous development of social economy and the acceleration of globalization, how to make people live healthier and longer and improve the quality of human life has become a global topic Biotechnology has been playing an active role in promoting human health since its birth Biopharmaceutical, which integrates the most cutting-edge technology, has changed the raw materials, processes and production methods of traditional pharmaceutical, and has helped mankind overcome many persistent diseases that threaten health To speed up the development of biopharmaceutical industry is not only to respond to the demand of promoting human health, but also to respond to the demand of improving national strength and promoting national economic development The primary task of promoting the development of biopharmaceutical industry is to promote technology exchange and international cooperation at home and abroad, so that the R & D and industrialization process of biopharmaceutical industry in China can be in line with international standards Under the guidance of the 13th five year plan and market demand, the domestic biopharmaceutical industry is developing rapidly In the booming biopharmaceutical industry, Xinda biopharmaceutical (Suzhou) Co., Ltd has gradually become an industry benchmark and the focus of industry experts, governments at all levels and international biopharmaceutical tycoons with its outstanding innovative industrial chain and international development mode in the short five-year development process On February 16, 2017, Mauro giacca, director general of the United Nations International Center for genetic engineering and biotechnology, visited Xinda Aiming at the only biopharmaceutical company visited, Dr Mauro giacca said that he was amazed at the rapid development of China's biopharmaceutical industry in recent years Xinda biology is undoubtedly the most iconic enterprise in this development wave The International Center for genetic engineering and Biotechnology (ICGEB) is an intergovernmental international science and technology organization of the United Nations It was founded in 1983 with the support of the United Nations Industrial Development Organization Its purpose and principle is to promote cooperation and exchange between developed and developing countries in the fields of genetic engineering and biotechnology, so that developing countries have the opportunity to participate in international research and training activities in these fields, so as to improve their national strength and promote national economic development As director general of ICGEB, Dr Mauro giacca has long been committed to promoting cooperation between developed and developing countries in the fields of genetic engineering and biotechnology During the visit, Dr Mauro giacca had a detailed understanding of the development of Cinda biology Founded in 2011, Xinda biology is committed to the development and production of new antibody drugs for the treatment of various difficult diseases endangering human health and life, so as to meet the huge demand of the domestic and foreign pharmaceutical market Since its establishment, the company has stood out among many domestic biopharmaceutical companies with its innovative research and development ideas and international operation mode, and has received the support of up to 490 million US dollars from several global famous venture capital funds, such as fidelity, Lilly Asia Fund, Junlian capital, Temasek, SDIC innovation, China Life insurance, China Ping An, etc A product chain including 12 new monoclonal antibody varieties has been established, covering four major disease fields, including tumor, fundus disease, autoimmune disease and cardiovascular disease Two of them have been selected into the national "major new drug creation" project, five of them have entered clinical research, and three of them have entered clinical phase III research Xinda bio has built a high-end bio pharmaceutical industrialization base, which conforms to the GMP standards of CFDA, FDA and EMA Two production lines have passed the GMP audit of International Pharmaceutical Group A team of high-end biopharmaceutical development and industrialization talents with international advanced level has been established, including more than 40 returnees Based on the products of independent innovation, Cinda biology has reached two comprehensive strategic cooperation with Lilly pharmaceutical group of the United States, with a total amount of 3.3 billion US dollars, creating several "first" in China Dr Yu Dechao, the founder and chairman of the company, was awarded "cctv2016 science and technology innovation figure", and also the "Long March 5" and "Tiangong 2" and "Shenzhou 11" manned mission development team The people's daily and the Wall Street Journal have published six long newsletters introducing the innovation ability and achievements of Cinda biology Dr Mauro giacca expressed his approval for Cinda's great achievements in just five years He understood that Cinda's current high-end industrial chain and industrialization level, as well as its multiple cooperation with international pharmaceutical giants, Mauro Dr giacca believes that as the leader of China's biopharmaceutical industry, Cinda will become the best biopharmaceutical company in China in its commercialization process, benefiting more patients In the exchange process, Dr Mauro giacca said that Cinda biology has been recognized by the industry and international pharmaceutical groups ICGEB will continue to play an organizational role, expand the exchange and cooperation between Cinda biology and other advanced enterprises and research institutions in other countries, so as to make the high-quality biological drugs developed and produced by Cinda that meet international standards benefit mankind as soon as possible Lawrence banks, director of cancer virology laboratory, Italy branch of ICGEB, Alessandro Marcello, director of molecular virology laboratory, Huang Jing, director of National Center for biology, Hua Yutao, director of chemical medicine and medical equipment department, Xu Penghui, director of International Cooperation Department, Yu Shanjiang, deputy director of Medical Biotechnology Department, etc visited together.